Author: Mark Gillies (Australia)
Co-authors:
Purpose
Continuous, indefinite treatment with anti-vascular endothelial growth factor (anti-VEGF) injections for neovascular age-related macular degeneration (nAMD) patients is essential to maintain visual acuity (VA) and prevent vision loss. However, this results in issues with long-term adherence to treatment. Patients treated under a treat-and-extend regimen will have variable treatment intervals based on disease activity of the choroidal neovascular (CNV) lesion, with shorter intervals (minimum 4 weeks) when disease is highly active and vice versa. It is plausible that patients on short treatment intervals, i.e., high treatment frequency, may be more likely to discontinue due to injection fatigue. Alternatively, the need for frequent treatment in high disease activity patients may indicate that discontinuing treatment would very quickly lead to vision loss and thus encourage them to adhere to treatment. We hypothesise that eyes with longer intervals would be more compliant as they are less susceptible to injection fatigue.
Setting/Venue
This was an observational study of real-world outcomes using data from the prospectively designed Fight Retinal Blindness! registry.
Methods
Treatment-naïve eyes in the Fight Retinal Blindness! registry initiating treatment for nAMD between 1st January 2013 and 31st December 2015 were identified. Eyes must have received a minimum of 4 injections with no large gaps between injections exceeding 365 days and treated for at least 18 months to reduce the likelihood of under-treatment. Eyes were grouped based on the number of injections received in the first 18 months: 4-6 injections, 7-9 injections, 10-12 injections, 13-15 injections, 16-18 injections, and 18-21 injections. The primary outcome was the proportion of dropouts between 18-60 months analysed using Kaplan-Meier survival curves. Hazard ratios were calculated using Cox proportional hazards models adjusted for gender, age, VA at 18 months, angiolesion subtype, and clustering of outcomes within eyes from the same patient and patients treated by the same practitioner.
Results
There were 1706 eyes from 1564 patients eligible for the analysis. The proportion of eyes lost to follow-up was highest when fewer injections were administered in the first 18 months and lowest in eyes that received more injections in the first 18 months. Injection frequency at 18 months was significantly associated with risk of dropout (P = 0.003). The estimated dropout rate at 60 months was 82%, 84%, 76%, 71%, 64% and 63% for eyes receiving 4-6 injections, 7-9 injections, 10-12 injections, 13-15 injections, 16-18 injections, and 18-21 injections at 18 months, respectively. Other factors significantly associated with risk of dropout included age (P < 0.001) and VA at 18 months (P < 0.001). As expected, the proportion of visits in which the CNV lesion was graded as active was highest in eyes receiving more injections. The proportion of visits graded as active at 18 months was 51%, 55%, 54%, 64%, 75%, and 81% for eyes receiving 4-6 injections, 7-9 injections, 10-12 injections, 13-15 injections, 16-18 injections, and 18-21 injections at 18 months, respectively. Although the activity decreased for all injection frequency groups over time, eyes that received more injections at 18 months continued to have the most activity throughout.
Conlusions
Contrary to our hypothesis, we found that eyes were more likely to be adherent with more frequent injections. We believe this is because patients receiving frequent treatment have high disease activity leading to the perception that continuing treatment is still effective and necessary to control it. In contrast, eyes on longer intervals with low disease activity may be less likely to perceive the benefits of continuing treatment and discontinue as a result. Clinicians may need to be more vigilant in ensuring patients on long intervals do not get complacent as they are at greater risk of discontinuing treatment.
Financial Disclosure
-
Comments
-